STOCK TITAN

XORTX Therapeutics Inc. - XRTX STOCK NEWS

Welcome to our dedicated page for XORTX Therapeutics news (Ticker: XRTX), a resource for investors and traders seeking the latest updates and insights on XORTX Therapeutics stock.

XORTX Therapeutics Inc. (NASDAQ: XRTX) is a bio-pharmaceutical company dedicated to developing and commercializing innovative therapies aimed at treating progressive kidney diseases worldwide. Headquartered in Calgary, Canada, XORTX focuses on addressing serious health conditions related to aberrant purine and uric acid metabolism, including diabetic nephropathy, polycystic kidney disease (PKD), and complications arising from diabetes and cardiovascular diseases.

The company has two lead programs targeting progressive kidney disease due to diabetes and PKD. Additionally, XORTX is actively involved in the development of uric acid-lowering agents to treat conditions like hypertension, insulin resistance, metabolic syndrome, and diabetes. Their pipeline includes xanthine oxidase inhibitors that show potential in managing diabetic nephropathy.

One of XORTX's strategic milestones is its alliance with Teijin Pharma Limited for the development of TMX-049, a promising xanthine oxidoreductase inhibitor. Another significant partnership is with the Icahn School of Medicine, focusing on studying acute kidney injury and hyperuricemia in patients hospitalized with COVID-19.

XORTX Therapeutics Inc. is at the clinical-stage of biotechnology, aiming to identify, develop, and potentially commercialize therapies that can slow or reverse the progression of chronic kidney diseases. Their focus includes addressing the immediate needs of individuals facing acute kidney injury (AKI) due to respiratory virus infections and exploring other opportunities where their intellectual property can mitigate various health issues.

Rhea-AI Summary

XORTX Therapeutics Inc. has successfully completed recruitment for the first part of the XRX-OXY-101 bridging pharmacokinetics study for its XRx-008 program aimed at treating autosomal dominant polycystic kidney disease (ADPKD). A total of 32 subjects have been dosed to evaluate the pharmacokinetics and bioavailability of the proprietary formulations of oxypurinol. The study will also gather essential data for a future 505(b)2 filing. ADPKD affects over 10 million people globally and the company aims to develop therapies to slow kidney function decline.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
57.76%
Tags
-
Rhea-AI Summary

XORTX Therapeutics has received Small and Medium Enterprise (SME) status in the EU, which will benefit its EMA interactions. This designation offers a 90% fee reduction for various regulatory services, aiding in the upcoming XRX-OXY-301 phase 3 trial for XRx-008. The trial aims to evaluate the safety and efficacy of XRx-008 in patients with ADPKD over 24 months, enrolling an estimated 350 patients. XORTX is also conducting a pharmacokinetics study, XRX-OXY-101, to assess the drug's safety and bioavailability, starting in Q2 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.52%
Tags
none
-
Rhea-AI Summary

XORTX Therapeutics Inc. announced the receipt of a no objection letter from Health Canada for its XRX-OXY-101 clinical bridging pharmacokinetics study. The study aims to identify the optimal formulation for oxypurinol and assess food effect, safety, and pharmacokinetics. This information is critical for advancing toward a phase 3 trial in Autosomal Dominant Polycystic Kidney Disease (ADPKD). Dr. Allen Davidoff emphasized that this milestone accelerates the development of the XRx-008 program towards potential marketing approvals for treating progressive kidney disease.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
Rhea-AI Summary

XORTX Therapeutics Inc. has announced the granting of a patent for its proprietary formulations in treating Autosomal Dominant Polycystic Kidney Disease (ADPKD). The patent, titled 'Formulations of Xanthine Oxidase Inhibitors,' provides 20 years of protection for XRx-008, aimed at addressing the unmet medical needs in progressive kidney diseases. Approximately 3 million individuals globally suffer from ADPKD. This patent strengthens XORTX's intellectual property portfolio in the U.S., paving the way for expanded clinical trials and partnership opportunities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.84%
Tags
none
-
News
Rhea-AI Summary

XORTX Therapeutics Inc. has filed an investigational new drug (IND) application with the FDA for its XRx-008 program targeting autosomal dominant polycystic kidney disease (ADPKD). This IND supports the initiation of clinical trials for a combination of uric acid-lowering agents aimed at slowing disease progression. Currently, few treatment options exist for ADPKD, with only one approved drug, Tolvaptan. The company aims to advance XRx-008 to provide better outcomes for patients, as recent evidence indicates that high uric acid levels are a risk factor for kidney function decline.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.04%
Tags
none
-
Rhea-AI Summary

XORTX Therapeutics has submitted a Patent Cooperation Treaty application for a patent titled “Compositions and Methods for Enhancing Anti-Viral Therapies”. This patent focuses on addressing purine metabolism and hyperuricemia, particularly in individuals at risk for severe COVID-19 outcomes, including those with obesity and chronic kidney disease. The submission is based on retrospective clinical data suggesting the potential for uric acid-lowering agents to inhibit SARS-CoV-2 replication. The company clarifies that it does not claim to cure or contain COVID-19.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
43.8%
Tags
none
Rhea-AI Summary

XORTX Therapeutics has submitted a clinical trial application for its XRX-OXY-101 bridging pharmacokinetics study to Health Canada. This study aims to evaluate the optimal formulation for circulating oxypurinol concentrations, assess food effects on bioavailability, and understand safety and pharmacokinetics. The results will inform future oral dosing for the planned phase 3 trial targeting Autosomal Dominant Polycystic Kidney Disease (ADPKD). The outcomes will also support marketing submissions to the FDA and EMA.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.74%
Tags
-
News
Rhea-AI Summary

XORTX Therapeutics Inc. (NASDAQ: XRTX) reported significant achievements in 2021 and outlined strategic goals for 2022. Key highlights include raising $20 million through equity financings, advancement of XRx-008 for ADPKD, and XRx-101 targeting acute kidney injury from COVID-19. The company secured several patents and engaged in partnerships with notable institutions like Mount Sinai Hospital. Upcoming plans include initiating clinical trials and seeking orphan drug designation to enhance its product pipeline aimed at improving patient outcomes in kidney diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.75%
Tags
none
-
Rhea-AI Summary

XORTX Therapeutics has appointed Dr. David MacDonald as the new Chief Technology Officer (CTO), enhancing its leadership with over 30 years of drug development expertise. Dr. MacDonald previously held senior roles at MSI Methylation Sciences and Active Pass Pharmaceutics, demonstrating a solid track record in R&D and clinical development. The company also issued 127,500 stock options priced at $2.54 CAD, set to expire in five years. XORTX focuses on developing therapies for progressive kidney diseases, with clinical products aimed at ADPKD and acute organ injury related to COVID-19.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.69%
Tags
management
Rhea-AI Summary

XORTX Therapeutics Inc. (NASDAQ: XRTX) announced its participation in the H.C. Wainwright BioConnect 2022 Virtual Conference from January 10-13, 2022. Dr. Allen Davidoff, CEO, will provide a company progress update and outline planned activities for 2022. A pre-recorded presentation will be available via a provided link. Dr. Davidoff expressed enthusiasm about the opportunity to engage with global investors and pharmaceutical partners during this busy week of meetings associated with the JP Morgan virtual conference.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences

FAQ

What is the current stock price of XORTX Therapeutics (XRTX)?

The current stock price of XORTX Therapeutics (XRTX) is $1.265 as of November 21, 2024.

What is the market cap of XORTX Therapeutics (XRTX)?

The market cap of XORTX Therapeutics (XRTX) is approximately 4.1M.

What is XORTX Therapeutics Inc.?

XORTX Therapeutics Inc. is a bio-pharmaceutical company focused on developing and commercializing therapies to treat progressive kidney diseases worldwide.

What are the main diseases XORTX targets?

XORTX targets progressive kidney diseases such as diabetic nephropathy, polycystic kidney disease, and complications from diabetes and cardiovascular diseases.

Where is XORTX Therapeutics headquartered?

XORTX Therapeutics Inc. is headquartered in Calgary, Canada.

What is TMX-049?

TMX-049 is a xanthine oxidoreductase inhibitor being developed by XORTX in collaboration with Teijin Pharma Limited.

Who are XORTX's strategic partners?

XORTX has strategic partnerships with Teijin Pharma Limited and the Icahn School of Medicine.

What stage is XORTX Therapeutics in?

XORTX Therapeutics Inc. is a clinical-stage biotechnology company.

What health issues does XORTX aim to address?

XORTX aims to address health issues related to aberrant purine and uric acid metabolism, such as diabetic nephropathy, hypertension, insulin resistance, and metabolic syndrome.

What is the focus of XORTX's pipeline?

The focus of XORTX's pipeline includes developing therapies to slow or reverse chronic kidney diseases and addressing acute kidney injury due to respiratory virus infections.

What are xanthine oxidase inhibitors?

Xanthine oxidase inhibitors are a class of drugs that reduce uric acid production and are being developed by XORTX to manage conditions like diabetic nephropathy.

How does XORTX contribute to COVID-19 research?

XORTX collaborates with the Icahn School of Medicine to study acute kidney injury and hyperuricemia in patients hospitalized with COVID-19.

XORTX Therapeutics Inc.

Nasdaq:XRTX

XRTX Rankings

XRTX Stock Data

4.06M
3.13M
3.02%
6.03%
0.07%
Biotechnology
Healthcare
Link
United States of America
Alberta Beach